skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Risperidone in the treatment of bipolar mania

(2819) Views  (487) Full article downloads

Authors: Martha Sajatovic, Subramoniam Madhusoodanan, Matthew A Fuller

Published Date February 2006 Volume 2006:2(2) Pages 127 - 138
DOI: http://dx.doi.org/10.2147/NDT.S

Martha Sajatovic1, Subramoniam Madhusoodanan2, Matthew A Fuller3

1Case Western Reserve University School of Medicine, Cleveland, OH, USA; 2Health Science Center at Brooklyn, New York, NY, USA; 3Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA

Abstract: Atypical antipsychotic medications have assumed growing importance for the treatment of bipolar disorder, an illness that affects approximately 1.2%–3.7% of the general population in a given year. Current practice guidelines for the treatment of bipolar mania support the use of atypical antipsychotic medications as monotherapy or as a component of polytherapy, and in clinical settings the use of atypical antipsychotics to treat bipolar disorder is widespread. Risperidone is an atypical antipsychotic, sometimes referred to as a secondgeneration antipsychotic. The receptor-binding profile of risperidone, which includes potent antagonism of the serotonin 5-HT2A, dopamine D2, and alpha-adrenergic receptors, is believed to be related to positive effects on mood. The FDA-approved bipolar indications for risperidone include: 1) monotherapy for short-term treatment of acute manic or mixed episodes associated with bipolar I disorder and 2) combination therapy with lithium or valproate for the shortterm treatment of acute manic or mixed episodes associated with bipolar I disorder. This review of risperidone for bipolar mania will address the chemistry, pharmacodynamics, pharmacokinetics, and metabolism of risperidone, use with concomitant medications, clinical trials in bipolar mania, as well as safety and tolerability issues. Finally, dosing and administration are addressed as well as use for bipolar mania in geriatric, child, or adolescent patients.

Keywords: risperidone, bipolar disorder, mania, antipsychotic, psychopharmacology








Readers of this article also read:

Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?
The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder
Bipolar disorders: treatment options and patient satisfaction
Update on ropinirole in the treatment of Parkinson’s disease
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
Restless legs syndrome: differential diagnosis and management with pramipexole
Ropinirole in restless legs syndrome and periodic limb movement disorder
Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection
Hyperbaric oxygen ameliorates worsening signs and symptoms of post-traumatic stress disorder